This Article Full Text Full Text (PDF) All Versions of this Article: 34/6/1437    most recent 01.STR.0000072513.72262.7Ev1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Wardlaw, J.M. Articles by Berge, E. Search for Related Content PubMed PubMed Citation Articles by Wardlaw, J.M. Articles by Berge, E. Pubmed/NCBI databases Substance via MeSH Medline Plus Health Information Stroke Related Collections Acute Cerebral Infarction Emergency treatment of Stroke Thrombolysis

(Stroke. 2003;34:1437.)
© 2003 American Heart Association, Inc.

Original Contributions

Thrombolytic Therapy With Recombinant Tissue Plasminogen Activator for Acute Ischemic Stroke

Where Do We Go From Here? A Cumulative Meta-Analysis

J.M. Wardlaw, MD, FRCR, FRCPE; P.A.G. Sandercock, DM, FRCPE, FMedSci E. Berge, MD

From the Department of Clinical Neurosciences, Western General Hospital, Edinburgh, UK.

Correspondence to Professor Joanna Wardlaw, Department of Clinical Neurosciences, Western General Hospital, Edinburgh EH4 2XU, Scotland, UK. E-mail jmw{at}skull.dcn.ed.ac.uk

Background and Purpose— Recombinant tissue plasminogen activator (rtPA; Actilyse) is not as widely used in clinical practice as it could be. Have new data since 1995 strengthened the evidence sufficiently to justify more widespread use of rtPA?

Methods— We performed a sequential year-to-year cumulative meta-analysis of randomized controlled trials of rtPA in acute ischemic stroke.

Results— Although the amount of data has doubled since 1995, effect estimates for key outcomes remain imprecise, and significant between-trial heterogeneity persists. In the most recent analysis, rtPA up to 6 hours after stroke yielded 55 fewer dead or dependent people per 1000 treated (95% CI, 18 to 92) despite some risk (nonsignificant excess of 19 deaths per 1000 patients treated; 95% CI, 6 fewer to 48 more). Severity of stroke, patient age, and aspirin use were possible sources of heterogeneity.

Conclusions— Despite doubling of the data since 1995, the magnitude of risks and benefits with rtPA remains imprecise. This gap in knowledge may be hindering clinical use of rtPA and can be filled only by new trials designed to address these specific issues.

Key Words: meta-analysis • stroke, acute • stroke, ischemic • thrombolytic therapy

This article has been cited by other articles:

				S. K. Natarajan, K. V. Snyder, A. H. Siddiqui, C. C. Ionita, L. N. Hopkins, and E. I. Levy Safety and Effectiveness of Endovascular Therapy After 8 Hours of Acute Ischemic Stroke Onset and Wake-Up Strokes Stroke, October 1, 2009; 40(10): 3269 - 3274. [Abstract] [Full Text] [PDF]

				C. Foerch, M. Sitzer, H. Steinmetz, T. Neumann-Haefelin, and for the Arbeitsgruppe Schlaganfall Hessen (ASH) Future Demographic Trends Decrease the Proportion of Ischemic Stroke Patients Receiving Thrombolytic Therapy: A Call to Set-Up Therapeutic Studies in the Very Old Stroke, May 1, 2009; 40(5): 1900 - 1902. [Abstract] [Full Text] [PDF]

				G. W. Albers, P. Amarenco, J. D. Easton, R. L. Sacco, and P. Teal Antithrombotic and Thrombolytic Therapy for Ischemic Stroke: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) Chest, June 1, 2008; 133(6_suppl): 630S - 669S. [Abstract] [Full Text] [PDF]

				E. J. Alegre and E. Rios Alteplase for Patients With Ictus: the Dilemma Persists Stroke, September 1, 2007; 38(9): e91 - e91. [Full Text] [PDF]

				M.S.V. Elkind, S. Prabhakaran, J. Pittman, W. Koroshetz, M. Jacoby, K. C. Johnston, and for the GAIN Americas Investigators Sex as a predictor of outcomes in patients treated with thrombolysis for acute stroke Neurology, March 13, 2007; 68(11): 842 - 848. [Abstract] [Full Text] [PDF]

				D. Nilsson, J. Wemer, Y.-F. Cheng, I. Reinholdsson, G. Englund, N. Egberg, and S. Schulman NXY-059 Does Not Affect Bleeding Time in Healthy Volunteers: A Randomized, Double-Blind, Placebo-Controlled, 3-Period Crossover Phase I Study J. Clin. Pharmacol., February 1, 2007; 47(2): 264 - 272. [Abstract] [Full Text] [PDF]

				T. Kurth, A. M. Walker, R. J. Glynn, K. A. Chan, J. M. Gaziano, K. Berger, and J. M. Robins Results of Multivariable Logistic Regression, Propensity Matching, Propensity Adjustment, and Propensity-based Weighting under Conditions of Nonuniform Effect Am. J. Epidemiol., February 1, 2006; 163(3): 262 - 270. [Abstract] [Full Text] [PDF]

				M. D. Hill Diagnostic Biomarkers for Stroke: A Stroke Neurologist's Perspective Clin. Chem., November 1, 2005; 51(11): 2001 - 2002. [Full Text] [PDF]

				M S Mouradian, A Senthilselvan, G Jickling, J A McCombe, D J Emery, N Dean, and A Shuaib Intravenous rt-PA for acute stroke: comparing its effectiveness in younger and older patients J. Neurol. Neurosurg. Psychiatry, September 1, 2005; 76(9): 1234 - 1237. [Abstract] [Full Text] [PDF]

				K. Tsuji, T. Aoki, E. Tejima, K. Arai, S.-R. Lee, D. N. Atochin, P. L. Huang, X. Wang, J. Montaner, and E. H. Lo Tissue Plasminogen Activator Promotes Matrix Metalloproteinase-9 Upregulation After Focal Cerebral Ischemia Stroke, September 1, 2005; 36(9): 1954 - 1959. [Abstract] [Full Text] [PDF]

				M. D. Hill, A. M. Buchan, and for The Canadian Alteplase for Stroke Effectivenes Thrombolysis for acute ischemic stroke: results of the Canadian Alteplase for Stroke Effectiveness Study Can. Med. Assoc. J., May 10, 2005; 172(10): 1307 - 1312. [Abstract] [Full Text] [PDF]

				M. A. Samuels Update in Neurology Ann Intern Med, January 4, 2005; 142(1): 28 - 36. [Full Text] [PDF]

				X. Wang, K. Tsuji, S.-R. Lee, M. Ning, K. L. Furie, A. M. Buchan, and E. H. Lo Mechanisms of Hemorrhagic Transformation After Tissue Plasminogen Activator Reperfusion Therapy for Ischemic Stroke Stroke, November 1, 2004; 35(11_suppl_1): 2726 - 2730. [Abstract] [Full Text] [PDF]

				P. U. Heuschmann, P. L. Kolominsky-Rabas, J. Roether, B. Misselwitz, K. Lowitzsch, J. Heidrich, P. Hermanek, C. Leffmann, M. Sitzer, M. Biegler, et al. Predictors of In-Hospital Mortality in Patients With Acute Ischemic Stroke Treated With Thrombolytic Therapy JAMA, October 20, 2004; 292(15): 1831 - 1838. [Abstract] [Full Text] [PDF]

				G. Saposnik, B. Young, B. Silver, S. Di Legge, F. Webster, V. Beletsky, V. Jain, Y. Nilanont, and V. Hachinski Lack of Improvement in Patients With Acute Stroke After Treatment With Thrombolytic Therapy: Predictors and Association With Outcome JAMA, October 20, 2004; 292(15): 1839 - 1844. [Abstract] [Full Text] [PDF]

				E. H. Lo, J. P. Broderick, and M. A. Moskowitz tPA and Proteolysis in the Neurovascular Unit Stroke, February 1, 2004; 35(2): 354 - 356. [Full Text] [PDF]

				Thrombolysis for Acute Ischemic Stroke: Net Benefit Despite Definite Hazards Journal Watch Neurology, December 12, 2003; 2003(1212): 3 - 3. [Full Text]